Shares of Can-Fite BioPharma Ltd. (CANF) are soaring about 92 percent on Wednesday morning trading following the announcement of results from its Phase IIa open-label study evaluating namodenoson in patients with advanced pancreatic ductal adenocarcinoma.
The company's shares are currently trading at $9.62 on the New York Stock Exchange, up 92.40 percent. The stock opened at $8.66 and has climbed as high as $10.40 so far in today's session. Over the past year, it has traded in a range of $3.40 to $46.60.
The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.